JGC
CHRS icon

J. Goldman & Co’s Coherus Oncology CHRS Stock Holding History

J. Goldman & Co’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-149,986
Closed -$2.79M – 314
2020
Q2 		$2.68M Buy
149,986
+15,624
+12% +$264K 0.17% 139
2020
Q1 		$2.18M Sell
134,362
-1,687
-1% -$31.2K 0.26% 92
2019
Q4 		$2.45M Buy
+136,049
New +$2.51M 0.18% 123

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

J. Goldman & Co's CHRS Position: Q3 2020 in Review

J. Goldman & Co sold out of Coherus Oncology (CHRS) in Q3 2020, closing a stake of 149,986 shares — an estimated $2.79M sold.

J. Goldman & Co first reported a position in CHRS in Q4 2019 and held it in 3 quarters. The position peaked at $2.68M in Q2 2020. 201 funds tracked by Wall St. Rank hold CHRS as of Q3 2020.

  • J. Goldman & Co reported no remaining Coherus Oncology position as of Q3 2020 after selling out during the quarter.
  • J. Goldman & Co sold 149,986 Coherus Oncology shares in Q3 2020, an estimated $2.79M.
  • J. Goldman & Co first reported a position in Coherus Oncology in Q4 2019 and held it in 3 quarters.
  • J. Goldman & Co's Coherus Oncology position peaked at $2.68M in Q2 2020.
  • 201 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2020.

Based on J. Goldman & Co's 13F filing for Q3 2020, filed 16 Nov 2020.